par Rothenberg, Marc E;Roufosse, Florence ;Faguer, Stanislas;Gleich, Gerald J;Steinfeld, Jonathan;Yancey, Steven W;Mavropoulou, Eleni;Kwon, Namhee;HES Mepolizumab Study Group,
Référence The journal of allergy and clinical immunology. In practice, 10, 9, page (2367-2374.e3)
Publication Publié, 2022-09
Référence The journal of allergy and clinical immunology. In practice, 10, 9, page (2367-2374.e3)
Publication Publié, 2022-09
Article révisé par les pairs
Résumé : | Mepolizumab, an anti-interleukin-5 (IL-5) antibody, reduces disease flares in patients with hypereosinophilic syndrome (HES). Factors predicting treatment response are unknown. |